Conditions: Transplant; Failure, Kidney Hypertension
Keywords: kidney transplant hypertension nebivolol metoprolol bystolic toprol
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 11
Healthy volunteers: no

Brief summary:
In an open label analysis, nebivolol has been shown to have a positive impact on quality of life in the general hypertensive population. That is, patients treated with nebivolol reported less side effects compared to those treated with metoprolol. Also, more nebivolol treated patients reached normalization of blood pressure. Although there is no data, it is believed that the impact would be similar in renal transplant recipients.

The primary goal of this study is to determine if nebivolol will improve the quality of life measurements of kidney transplant recipients as compared to those treated with metoprolol succinate. This will be measured by comparing the scores of four quality of life questionnaires taken before and after 12 weeks of treatment with study drug. Other aims of this study are to determine if the use of nebivolol is cost-effective in the renal transplant recipient; determine if there is a change in urine protein excretion and renal function with the use of nebivolol; and determine the number of patients that maintain or achieve a target blood pressure of ≤ 120/80 mmHg.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Nebivolol intervention 2: Metoprolol succinate
Intervention descriptions: intervention 1: Subject will take nebivolol daily for 12 weeks. intervention 2: Subject will take metoprolol succinate daily for 12 weeks.

Protocol document: